Strategic Collaboration Target pharmaceutical and biotech companies seeking GLP/GMP CRO support for CMC, bioanalytical, and impurity studies. Primera’s broad service menu and FDA standing position it as a potential partner for manuscript-ready data generation, method development, and transfer across small and large molecules, including complex cell and gene therapy workflows.

Bioanalytical Excellence Leverage Primera’s capabilities in bioanalytical methods, PK/PD, ADA, and cell-based assays to pursue opportunities with sponsors needing robust validation, transfer, and regulatory-ready analytics, especially for bioavailability and bioequivalence programs.

Regulatory Readiness Emphasize access to GLP and GMP compliant testing with FDA alignment to win business from companies navigating tight regulatory timelines, IND/CTA submissions, and quality-focused CRO partnerships for release testing, stability, and impurity profiling.

Specialized Capabilities Position as a go-to partner for Cell & Gene Therapy analytics, including FACS, qPCR, ddPCR, and potency assays, plus advanced impurity and extractable/leachable studies, to capture demand from biotech startups and mature sponsors expanding into complex modalities.

Industry Footprint Highlight the mid-market scale and solid revenue band to appeal to mid-to-large biopharma and contract sponsors seeking a flexible, responsive CRO with extensive testing repertoire and a track record of industry events and community presence.